Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
541-560 of 1,694 trials

Non-Small Cell Lung Cancer: Divarasib with Other Therapies

We are studying the safety and effectiveness of divarasib combined with pembrolizumab and chemotherapy in patients with untreated advanced lung cancer that has a KRAS G12C mutation. This research aims to find the best dose and treatment approach.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Plaque Psoriasis: ESK-001 Treatment Study

We are testing a new medication, ESK-001, for people with moderate to severe plaque psoriasis. The study aims to see if it works better than a placebo and an existing treatment.

Moderate to Severe Plaque Psoriasis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

Atrial Fibrillation: Amiodarone Treatment Study

We are studying whether a longer or shorter course of amiodarone helps people with persistent atrial fibrillation return to a normal heart rhythm before a procedure. This may improve outcomes for patients undergoing electrical cardioversion.

Atrial Fibrillation1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCardiology

Ruxolitinib Rollover Study for Cancer Patients

We are providing continued access to ruxolitinib for patients who have previously participated in related studies. The goal is to evaluate the safety of ruxolitinib alone or with other cancer treatments.

MyelofibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Familial Hypercholesterolemia: Inclisiran Safety Study

We are studying the long-term safety and tolerability of inclisiran in individuals with familial hypercholesterolemia who have completed earlier studies. This research aims to understand how well the treatment works over time.

Familial Hypercholesterolemia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Advanced Solid Tumors: AZD8421 Study

We are testing a new drug, AZD8421, to see how safe it is and how well it works for people with advanced or metastatic solid tumors. This study will help us understand its effects alone and in combination with other cancer treatments.

ER+ HER2- Advanced Breast CancerHigh-Grade Serous Ovarian Cancer (HGSOC)Safety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

ACP-204 for Alzheimer's Disease Psychosis

We are testing the effects of ACP-204 in adults with Alzheimer's disease psychosis to see if it helps improve symptoms compared to a placebo.

Alzheimer's DiseaseAlzheimer's Disease Psychosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

HER2-Low Metastatic Breast Cancer: DB-1303 vs Chemotherapy

We are studying a new treatment, DB-1303, for patients with HER2-low, hormone receptor-positive metastatic breast cancer. The goal is to see if it works better than standard chemotherapy after previous treatments have failed.

Hormone Receptor Positive Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ongoing Treatment with Durvalumab for Cancer Patients

We are providing continued treatment for patients who have benefited from Durvalumab in a previous study. The focus is on monitoring safety and tolerability during this ongoing care.

Advanced Non-Small Cell Lung CancerPost-Chemotherapy Urothelial CarcinomaExtensive Stage Small-Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Alzheimer's Disease Psychosis: ACP-204 Study

We are examining the long-term safety and tolerability of ACP-204 in adults with Alzheimer's Disease Psychosis. This study helps us understand how well patients can handle this treatment over time.

Alzheimer's Disease Psychosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Pulmonary Fibrosis: Long-Term Study of BI 1015550

We are investigating the long-term safety and effectiveness of BI 1015550 in patients with pulmonary fibrosis who have previously participated in related studies. This study aims to understand how well the treatment is tolerated and its potential benefits.

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Pancreatic Cancer: Testing Enzyme Therapy

We are studying whether pancreatic enzyme replacement therapy can help patients with unresectable pancreatic cancer gain weight and improve their nutrition. This may enhance their quality of life and ability to handle chemotherapy.

Pancreatic Exocrine Insufficiency6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Thalassemia and Myelodysplastic Syndromes: SP-420 Treatment Study

We are investigating a new treatment, SP-420, for individuals with transfusion-dependent thalassemia or low-risk myelodysplastic syndromes. The study aims to find the right dose and evaluate its effectiveness in reducing excess iron and its safety.

Thalassemia and Myelodysplastic Syndromes6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Multiple Myeloma: Iberdomide with Isatuximab

We are studying whether adding isatuximab to iberdomide helps patients with newly diagnosed multiple myeloma achieve better treatment outcomes after stem cell transplantation.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Zolpidem Responses: Understanding Effects in Different Patients

We are investigating how zolpidem affects people with disorders of consciousness, vision impairments, and healthy volunteers. This study aims to uncover why some individuals respond differently to the medication.

Vision ImpairmentsDisorders of ConsciousnessHealthy Volunteers≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurologyPsychiatry

Chronic Obstructive Pulmonary Disease: New Inhaler Study

We are evaluating a new inhaler that combines Budesonide, Glycopyrronium, and Formoterol for people with COPD. The goal is to see if it improves heart and lung health compared to current treatments.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePulmonology

Oral Vancomycin for Primary Sclerosing Cholangitis

We are studying whether oral vancomycin can improve liver health in adults and young patients with Primary Sclerosing Cholangitis. The trial will also look at the safety of the treatment and its effects on related health conditions.

Primary Sclerosing Cholangitis3-6 monthsEfficacy phase (II)Standard MedicinesGastroenterologyHepatology

Breast Cancer Surgery: Ketorolac and Pregabalin Study

We are exploring how preoperative use of ketorolac and pregabalin affects inflammation and pain in breast cancer patients. This study looks at how these effects may vary based on body weight.

Estrogen Receptor Positive Breast Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

COVID-19 Treatment: RECOVERY Trial

We are studying various treatments for COVID-19 to see if they can reduce death rates and help patients leave the hospital sooner. We also want to find out if these treatments can prevent severe breathing issues.

Pneumonia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Chronic Kidney Disease: CKD-bioMatch Study

We are exploring whether a new treatment based on biomarkers can improve kidney function in patients with chronic kidney disease compared to standard care. This study aims to find better ways to manage CKD and its effects.

Chronic Kidney Disease>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementNephrology